NCT06224673View on ClinicalTrials.gov

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast CancerHormone Receptor Positive Breast Carcinoma
Interventions
DRUG

ARX788

Given IV

PROCEDURE

Computed Tomography (CT)

Undergo CT or Positron Emission Tomography(PET)/CT

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Amiloride

Ophthalmologic drops given topically to participants for an eye toxicity substudy

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Ambrx, Inc.

INDUSTRY

lead

Laura Huppert, MD, BA

OTHER